EA200971093A1 - Терапевтические композиции и их применение - Google Patents

Терапевтические композиции и их применение

Info

Publication number
EA200971093A1
EA200971093A1 EA200971093A EA200971093A EA200971093A1 EA 200971093 A1 EA200971093 A1 EA 200971093A1 EA 200971093 A EA200971093 A EA 200971093A EA 200971093 A EA200971093 A EA 200971093A EA 200971093 A1 EA200971093 A1 EA 200971093A1
Authority
EA
Eurasian Patent Office
Prior art keywords
pharmaceutically acceptable
acceptable salt
application
therapeutic compositions
compositions
Prior art date
Application number
EA200971093A
Other languages
English (en)
Inventor
Брайан П. Кирни
Анита А. Матиас
Сринивасан Раманатан
Original Assignee
Джилид Сайэнс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Джилид Сайэнс, Инк. filed Critical Джилид Сайэнс, Инк.
Publication of EA200971093A1 publication Critical patent/EA200971093A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Quinoline Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Настоящее изобретение включает способы, композиции и наборы, подходящие для лечения вирусной инфекции путем введения 6-(3-хлор-2-фторбензил)-1-[(2S)-1-гидрокси-3-метилбутан-2-ил]-7-метокси-4-оксо-1,4-дигидрохинолин-3-карбоновой кислоты или фармацевтически приемлемой соли указанного соединения совместно с атазанавиром (atazanavir) или его фармацевтически приемлемой солью и, возможно, с соединением, ингибирующим цитохром Р-450, или фармацевтически приемлемой солью указанного соединения.
EA200971093A 2007-06-29 2008-06-26 Терапевтические композиции и их применение EA200971093A1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US94730607P 2007-06-29 2007-06-29
US4092008P 2008-03-31 2008-03-31
PCT/US2008/068339 WO2009006199A1 (en) 2007-06-29 2008-06-26 Therapeutic compositions and the use thereof

Publications (1)

Publication Number Publication Date
EA200971093A1 true EA200971093A1 (ru) 2010-08-30

Family

ID=39831893

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200971093A EA200971093A1 (ru) 2007-06-29 2008-06-26 Терапевтические композиции и их применение

Country Status (19)

Country Link
US (4) US20090093467A1 (ru)
EP (1) EP2167088A1 (ru)
JP (3) JP5547066B2 (ru)
KR (1) KR20100040892A (ru)
CN (2) CN101686972B (ru)
AP (1) AP2965A (ru)
AR (1) AR067183A1 (ru)
AU (1) AU2008270630B2 (ru)
BR (1) BRPI0813000A2 (ru)
CA (1) CA2692101A1 (ru)
CO (1) CO6251237A2 (ru)
EA (1) EA200971093A1 (ru)
EC (1) ECSP109897A (ru)
IL (1) IL202744A0 (ru)
MX (1) MX2009013829A (ru)
NZ (1) NZ582086A (ru)
SG (1) SG182229A1 (ru)
TW (1) TW200914011A (ru)
WO (1) WO2009006199A1 (ru)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1976517A1 (en) * 2005-12-30 2008-10-08 Gilead Sciences, Inc. Methods for improving the pharmacokinetics of hiv integrase inhibitors
AU2007275860C1 (en) 2006-07-07 2014-06-12 Gilead Sciences, Inc. Modulators of pharmacokinetic properties of therapeutics
JP5221544B2 (ja) 2006-09-12 2013-06-26 ギリアード サイエンシーズ， インコーポレイテッド インテグラーゼ阻害剤を調製するためのプロセスおよび中間体
ES2602784T3 (es) * 2007-02-23 2017-02-22 Gilead Sciences, Inc. Moduladores de las propiedades farmacocinéticas de los agentes terapéuticos
CN101686972B (zh) * 2007-06-29 2013-08-14 吉里德科学公司 治疗用组合物和方法
CA2691736A1 (en) * 2007-06-29 2009-01-08 Gilead Sciences, Inc. Combination of 6-(3-chloro-2-fluorobenzyl)-1-[(2s)-1-hydroxy-3-methylbutan-2-yl]-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid and lopinavir for the treatment of a viral infection in a human
AR068403A1 (es) * 2007-09-11 2009-11-18 Gilead Sciences Inc Proceso e intermediarios para la preparacion de inhibidores de integrasa
AU2009242451C1 (en) 2008-05-02 2017-05-18 Gilead Sciences, Inc. The use of solid carrier particles to improve the processability of a pharmaceutical agent
CN102917695A (zh) * 2010-04-09 2013-02-06 百时美施贵宝公司 具有改进的pH效应的阿扎那韦硫酸盐制剂
US20130274254A1 (en) * 2010-12-21 2013-10-17 Gilead Sciences, Inc. Inhibitors of cytochrome p450 (cyp3a4)
WO2013082476A1 (en) 2011-11-30 2013-06-06 Emory University Antiviral jak inhibitors useful in treating or preventing retroviral and other viral infections
PT2880017T (pt) 2012-08-03 2016-12-14 Gilead Sciences Inc Processo e intermediários para preparar inibidores da integrase
PT3608325T (pt) 2012-12-21 2022-10-17 Gilead Sciences Inc Compostos carbamoílpiridona policíclicos e sua utilização farmacêutica
NO2865735T3 (ru) 2013-07-12 2018-07-21
ES2645192T3 (es) 2013-07-12 2017-12-04 Gilead Sciences, Inc. Compuestos de carbamoilpiridona policíclica y su uso para el tratamiento de infecciones por VIH
US9463194B2 (en) 2014-02-05 2016-10-11 Gilead Sciences, Inc. Methods of treating patients co-infected with HIV and tuberculosis
TWI677489B (zh) 2014-06-20 2019-11-21 美商基利科學股份有限公司 多環型胺甲醯基吡啶酮化合物之合成
NO2717902T3 (ru) 2014-06-20 2018-06-23
TW201613936A (en) 2014-06-20 2016-04-16 Gilead Sciences Inc Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide
TWI695003B (zh) 2014-12-23 2020-06-01 美商基利科學股份有限公司 多環胺甲醯基吡啶酮化合物及其醫藥用途
BR112017013858A2 (pt) 2014-12-26 2018-02-27 Univ Emory n4-hidroxicitidina e derivados e usos antivirais relacionados aos mesmos
WO2016161382A1 (en) 2015-04-02 2016-10-06 Gilead Sciences, Inc. Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
BR112020010581A2 (pt) 2017-12-07 2020-11-10 Emory University composição farmacêutica, recipiente pressurizado, e, métodos para tratar ou prevenir uma infecção viral e de tratamento ou prevenção de coronavírus humano, sars, coronavírus mers, vírus da encefalite equina oriental, vírus da encefalite equina ocidental, vírus da encefalite equina venezuelana, vírus chikungunya e infecção por infecção de ross river, vírus orthomyxoviridae ou vírus paramyxoviridae ou vírus rsv, ou infecção pelo vírus influenza a e vírus influenza b ou vírus filoviridae ou vírus ebola.

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5696270A (en) * 1989-05-23 1997-12-09 Abbott Laboratories Intermediate for making retroviral protease inhibiting compounds
GB8927913D0 (en) * 1989-12-11 1990-02-14 Hoffmann La Roche Amino acid derivatives
US5413999A (en) * 1991-11-08 1995-05-09 Merck & Co., Inc. HIV protease inhibitors useful for the treatment of AIDS
US5484926A (en) * 1993-10-07 1996-01-16 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
US5914332A (en) * 1995-12-13 1999-06-22 Abbott Laboratories Retroviral protease inhibiting compounds
US5849911A (en) * 1996-04-22 1998-12-15 Novartis Finance Corporation Antivirally active heterocyclic azahexane derivatives
US6087383A (en) * 1998-01-20 2000-07-11 Bristol-Myers Squibb Company Bisulfate salt of HIV protease inhibitor
US6544540B2 (en) * 1998-07-29 2003-04-08 Syngenta Limited Base-triggered release microcapsules
BRPI0306214B1 (pt) * 2002-11-20 2017-08-08 Japan Tobacco Inc. 4-oxoquinoline compound and use of this as a hiv integrase inhibitor
MY134672A (en) * 2004-05-20 2007-12-31 Japan Tobacco Inc Stable crystal of 4-oxoquinoline compound
EP3287130A1 (en) * 2004-05-21 2018-02-28 Japan Tobacco Inc. Combinations comprising a 4-isoquinolone derivative and protease inhibitors
US20060058286A1 (en) * 2004-09-16 2006-03-16 Mark Krystal Methods of treating HIV infection
US20090233964A1 (en) * 2005-12-30 2009-09-17 Gilead Sciences, Inc. Methods for improving the pharmacokinetics of hiv integrase inhibitors
EP1976517A1 (en) * 2005-12-30 2008-10-08 Gilead Sciences, Inc. Methods for improving the pharmacokinetics of hiv integrase inhibitors
AU2007275860C1 (en) * 2006-07-07 2014-06-12 Gilead Sciences, Inc. Modulators of pharmacokinetic properties of therapeutics
JP5221544B2 (ja) * 2006-09-12 2013-06-26 ギリアード サイエンシーズ， インコーポレイテッド インテグラーゼ阻害剤を調製するためのプロセスおよび中間体
CN101686972B (zh) * 2007-06-29 2013-08-14 吉里德科学公司 治疗用组合物和方法
CA2691736A1 (en) * 2007-06-29 2009-01-08 Gilead Sciences, Inc. Combination of 6-(3-chloro-2-fluorobenzyl)-1-[(2s)-1-hydroxy-3-methylbutan-2-yl]-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid and lopinavir for the treatment of a viral infection in a human
AR068403A1 (es) * 2007-09-11 2009-11-18 Gilead Sciences Inc Proceso e intermediarios para la preparacion de inhibidores de integrasa
AU2009242451C1 (en) * 2008-05-02 2017-05-18 Gilead Sciences, Inc. The use of solid carrier particles to improve the processability of a pharmaceutical agent
US20110000941A1 (en) * 2009-07-06 2011-01-06 Volk J Patrick Apparatus and System for Carrying a Digital Media Player

Also Published As

Publication number Publication date
AU2008270630A1 (en) 2009-01-08
AU2008270630B2 (en) 2014-01-16
US20140343063A1 (en) 2014-11-20
CN103480000A (zh) 2014-01-01
TW200914011A (en) 2009-04-01
JP2010532372A (ja) 2010-10-07
BRPI0813000A2 (pt) 2014-12-23
ECSP109897A (es) 2010-03-31
NZ582086A (en) 2012-07-27
JP2013199495A (ja) 2013-10-03
SG182229A1 (en) 2012-07-30
KR20100040892A (ko) 2010-04-21
JP5547066B2 (ja) 2014-07-09
US20100331331A1 (en) 2010-12-30
US20170136001A1 (en) 2017-05-18
CN101686972A (zh) 2010-03-31
WO2009006199A1 (en) 2009-01-08
US20090093467A1 (en) 2009-04-09
IL202744A0 (en) 2010-06-30
AP2965A (en) 2014-09-30
CN101686972B (zh) 2013-08-14
MX2009013829A (es) 2010-03-10
CO6251237A2 (es) 2011-02-21
JP2015143278A (ja) 2015-08-06
EP2167088A1 (en) 2010-03-31
JP5769763B2 (ja) 2015-08-26
CA2692101A1 (en) 2009-01-08
AR067183A1 (es) 2009-09-30
AP2009005074A0 (en) 2009-12-31

Similar Documents

Publication Publication Date Title
EA200971093A1 (ru) Терапевтические композиции и их применение
EA200971096A1 (ru) Терапевтические композиции и их применение
EA201291301A1 (ru) Производные 2-хинолинилуксусной кислоты в качестве противовирусных соединений против вич
MX2018009633A (es) Inhibidor de indoleamina-2,3-dioxigenasa (ido).
PH12015502056A1 (en) Benzothiazole compounds and their pharmaceutical use
BR112012003578A8 (pt) Composto, sal farmaceuticamente aceitável, sal de sulfato, composição farmacêutica, método para tratar uma infecção viral, e, uso de um composto ou sal
EA200870193A1 (ru) Цитотоксические агенты, включающие новые производные томаймицина, и их терапевтическое применение
WO2014134566A3 (en) Amide compounds for the treatment of hiv
EA201391720A1 (ru) Замещенные диоксопиперидинилфталимидные производные
EA201390908A1 (ru) Производные бицикло[3.2.1]октиламида и их применение
EA201270247A1 (ru) Способы применения с-мет-модуляторов
MX2012015097A (es) Derivados de acido naft-2-ilacetico para tratar sida.
EA201390428A1 (ru) Композиции и способы лечения легочной гипертензии
EA200901241A1 (ru) Соединения для лечения гепатита с
BR112012026767A2 (pt) composto, sal farmaceuticamente aceitável de um composto, composição farmacêutica, método para tratar ou previnir distúrbios, e, uso de um composto ou sal
EA201290053A1 (ru) Ингибиторы вирусов flaviviridae
EA201290632A1 (ru) Производные бетулина
EA201290416A1 (ru) Новые спиропиперидиновые соединения
EA201170441A1 (ru) Терапевтические противовирусные пептиды
AU2011286276A8 (en) Substituted Biphenylene Compounds and methods of use thereof for the treatment of viral diseases
EA201001196A1 (ru) Соединения 4-пиридинона и их применение для лечения рака
EA201270275A1 (ru) Кристаллическое соединение пиридазина
EA201000895A1 (ru) Композиции и способы для лечения лизосомных болезней
EA201190293A1 (ru) Пролекарства триптолида
EA200700550A1 (ru) Производные алкилидентетрагидронафталина, способ их получения и их применение в качестве противовоспалительных средств